Showing results (381-390 of 630) with videos related to
Sort By:
Pageof 63
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 21, 2018
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional studyJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 10, 2018
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.American Journal of Clinical Dermatology|May 6, 2021
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported OutcomesJonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, et al.The Journal of Investigative Dermatology|April 23, 2019
Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 11, 2017
Burden of skin pain in atopic dermatitisParas P Vakharia, Rishi Chopra, Ryan Sacotte, et al.JMIR Formative Research|March 28, 2023
Engagement, Retention, and Acceptability in a Digital Health Program for Atopic Dermatitis: Prospective Interventional StudySigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L Ámundadóttir, et al.Eclinicalmedicine|February 23, 2023
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyHoward Sofen, Robert Bissonnette, Gil Yosipovitch, et al.Journal of the American Academy of Dermatology|September 30, 2024
The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 studyAmy S Paller, Jonathan I Silverberg, Eric L Simpson, et al.The Journal of Allergy and Clinical Immunology. Global|December 26, 2025
Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimabJie Li, Coryandar Gilvary, Lu Gao, et al.Dermatitis : Contact, Atopic, Occupational, Drug|December 18, 2023
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®Jonathan I Silverberg, Marjolein de Bruin-Weller, Brian M Calimlim, et al.Pageof 63